TrialInvestigational new drugs2013

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).

Philipp Harter et al.PubMed ↗Publisher ↗

No numbers read from the abstract.